More than 30 years in diagnostic innovation solutions

Our inception came about in Padua, in 1988, as a result of our innovation-focused vision, and it is thanks to this foundational principle that we now embody innovation itself.

Intuition, entrepreneurship and innovation: the values that led Dr Paolo Galiano to utilise his decades-long experience in laboratory diagnostics to found Alifax, a revolutionary company, that is now one of the leading international players in the haematology, microbiology, molecular biology, serology and autoimmunity fields.

Our history and successes

Alifax has always focused on new products and innovation, thanks to continuous stimuli which are essential for this sector

TEST1 is one of our first great successes: back in the 90s, it completely revolutionised the way in which the erythrocyte sedimentation rate was analysed, by retrieving reliable results in just 20 seconds, thanks to quantitative capillary photometry

This patented technology can now be found in over 10,000 installations worldwide and has resulted in a considerable expansion – even on the foreign markets – by means of the industry’s largest multinational companies

OVER 30 YEARS OF SUCCESS

 

We owe all that we have become today to many factors: perseverance, commitment, research, the ability to question ourselves and a constant relationship-focused attention

As Dr Paolo Galiano says: “Success is achieved whenever the end customer recognises that a winning product has been invented”

null

1988

Foundation

1992

Uro-quick market launch
null

1997

TEST1 market launch
null

1998

Sire Analytical

Systems acquisition

1998

First international publication on Test1 technology (Plebani, Am J Clin Pathol)

2003

First ESR international congress in Busan, South Korea
null

2004

Roller 20 market launch

2004

European partnership with Beckman Coulter

2005

Alfred60 and ESR quality Controls market launch
null

2006

Opening of the new facilities in Polverara, Padova

2007

First publication about ESR Latex controls (Piva, Clin Biochem)

2009

First publication about Human Biological Liquid culture (Fontana, Med Sci Monit)

2009

Publication on Test 1 ESR results in patients suffering from different diseases (Cha, Am J Clin Pathol)
null

2010

PenOK sample collection

devices market launch

2012

US market introduction
null

2012

Opening of the new R&D

and production site in Nimis,

Udine

2013

Sidecar market launch

2015

2015 Opening of 3 subsidiaries in Moscow, Shanghai, Barcelona

2017

Inauguration of the new building in Polverara
null

2017

Opening of the new

Alifax R&D in Area Science Park, Trieste

2018

Opening the subsidiary

Alifax Brazil

2018

30th anniversary celebration
null

2019

New Logo

2020

Opening of the new subsidiary in Germany
null

2021

I-dOne market launch
null

2022

Molecular Mouse market launch
null

2022

NEW TEST1 2.0

market launch

Ho avuto la fortuna di conoscere grandi persone,
capaci di insegnare ma anche di ascoltare
Scienziati dotati di onestà intellettuale
Il mio credo è esistere, e nel mondo industriale,
significa creare un progetto vincente

Paolo Galiano – Founder

2019 WORLD CHAMPIONS
ORC CLASS B

We work together to optimise your laboratory

Our products are designed and tested at length. When designing and developing products, we constantly collaborate with our customers to understand how the product will be used on a daily basis in their laboratories, in addition to their needs and requirements

For this reason, we offer them technological solutions that are ever easier to use: we know how important it is to optimise laboratory space and time

DISCOVER OUR PRODUCTION

Do you need information?


    ESR Line
    Bacteriology Line


    MDRO
    I-dOne


    Molecular Mouse
    Pen OK Saliva

    I hereby declare that I have read the Privacy Policy and at the same time * I hereby declare that I have read the Privacy Policy and at the same time

    I
    With the processing of my personal data in order to receive by e-mail newsletters and/or invitations to events/trainings or subscription to events in which the Data Controller is involved or organised by the Data Controller and/or by its parent/subsidiary and/or associated companies. Consent may be revoked at any time.